Delivery Order SPE2DB22D3019-SPE2DB25FK3ZK
- Not listed
- The Defense Logistics Agency awarded a $8,318.78 delivery order to AmerisourceBergen Drug Corp for MONOVISC 88 mg/4 mL syringes (4 mL quantity) on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract features firm fixed pricing and represents a routine pharmaceutical supply delivery. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $5,388.87 delivery order to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 mg/4 ml syringes (4 ml quantity) under a firm fixed price contract type. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The U.S. Defense Logistics Agency (DLA) awarded a $5,268.40 firm fixed-price delivery order to Amerisourcebergen Drug Corporation's Corporate Office Division for the supply of 4,565,285,746 units of the MONOVISC 88 MG/4 ML SYRINGE 4ML medical product. This delivery order was issued under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical and medical...
- The Defense Logistics Agency awarded a delivery order valued at $6,708.32 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on July 24, 2025, with completion expected by July 25, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,529.38 firm fixed-price contract is for the supply of MONOVISC 88 MG/4 ML SYRINGE 4ML, a medical product, with a completion date of February 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $6,266.96 on July 18, 2025, for the supply of MONOVISC 88 mg/4 mL syringes (4 mL quantity) under a firm fixed-price contract. The award, which carries an ultimate completion date of July 21, 2025, was funded by the Defense Logistics Agency's Medical Supply Chain division and performed at the company's corporate office location in Conshohocken, Pennsylvania. This non-competitive delivery order represents a continuation of...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $8,859.06 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of 4,562,814,068 units of MONOVISC 88 MG/4 ML SYRINGE 4ML. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
- The Defense Logistics Agency awarded a $2,155.93 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Monovisc is a hyaluronic acid-based injection used for knee osteoarthritis treatment, representing a specialized...
- This is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,564,792,418 units of the MONOVISC 88 MG/4 ML SYRINGE 4ML medical product. The $20,129.39 firm-fixed-price contract has a completion date of June 4, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $10,695.27 firm fixed-price contract is for the delivery of MONOVISC 88 MG/4 ML SYRINGE 4ML, a medical product used in healthcare. The contract has an ultimate completion date of November 22, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK3ZKDelivery Order
The Defense Logistics Agency awarded a $1,471.36 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price contract, which is not set-aside, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical and medical supply support to the Defense Health Agency and broader military healthcare systems. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen has demonstrated capability to supply diverse medical commodities ranging from specialty medications to medical devices through competitive federal contracting. The broader SPE2DX IDC enables the company to fulfill pharmaceutical needs across multiple therapeutic domains in support of global military healthcare operations and programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/25/25 |